Short Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Drops By 27.8%

Athira Pharma, Inc. (NASDAQ:ATHA) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 66,600 shares, a decrease of 27.8% from the September 30th total of 92,300 shares. Based on an average daily volume of 27,800 shares, the short-interest ratio is presently 2.4 days. Approximately 1.8% of the company’s shares are short sold. Approximately 1.8% of the company’s shares are short sold. Based on an average daily volume of 27,800 shares, the short-interest ratio is presently 2.4 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Athira Pharma stock. BML Capital Management LLC increased its position in Athira Pharma, Inc. (NASDAQ:ATHA) by 15.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,200,667 shares of the company’s stock after purchasing an additional 424,782 shares during the quarter. Athira Pharma accounts for 0.7% of BML Capital Management LLC’s portfolio, making the stock its 19th largest position. BML Capital Management LLC owned 8.20% of Athira Pharma worth $912,000 at the end of the most recent quarter. Institutional investors own 57.12% of the company’s stock.

Athira Pharma Stock Down 1.6%

Shares of Athira Pharma stock traded down $0.07 during trading hours on Monday, hitting $4.10. The company’s stock had a trading volume of 5,638 shares, compared to its average volume of 34,037. Athira Pharma has a 1-year low of $2.20 and a 1-year high of $8.26. The business has a fifty day moving average of $3.95 and a 200 day moving average of $3.55. The company has a market capitalization of $16.13 million, a PE ratio of -0.26 and a beta of 3.05.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings data on Thursday, August 7th. The company reported ($1.80) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.80). On average, sell-side analysts anticipate that Athira Pharma will post -2.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a research report on Wednesday, October 8th. Mizuho set a $4.00 price objective on shares of Athira Pharma in a research report on Friday, September 19th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell” and a consensus price target of $4.00.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.